CN1319400A - Epiderm specificity transfer factor - Google Patents
Epiderm specificity transfer factor Download PDFInfo
- Publication number
- CN1319400A CN1319400A CN01106777A CN01106777A CN1319400A CN 1319400 A CN1319400 A CN 1319400A CN 01106777 A CN01106777 A CN 01106777A CN 01106777 A CN01106777 A CN 01106777A CN 1319400 A CN1319400 A CN 1319400A
- Authority
- CN
- China
- Prior art keywords
- transfer factor
- epiderm
- animal
- specificity
- immunity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The epidermal specific transfer factor relates to the field of biotechnology, using animal transfer factor to cure human diseases, and is characterized that specific transfer factor extracted from leukocytic interior of sheep specifically immunized with keratin by means of dialysis method is used to specifically raise and regulate immunological function of cell, and cure various skin diseases due to immunological dysfunction.
Description
The present invention relates to biotechnology.
Use dissolved leukocyte extract first from nineteen ninety-five Lawrence, be injected in responsive receptor, proof has the transmission delayed hypersensitivity, name and be " transfer factor ", transfer factor is a kind of small-molecular weight (＜5000D) polypeptide and nucleotide, its activity is not destroyed by trypsin, ribonuclease, can be oral.Its very low dose of 0.01 unit just can make normal receptor produce part or general reaction, can make receptor sensitization within a short period of time, in a single day sensitization is transferred to after the receptor, retention time can reach about 1 year, itself does not contain globulin, do not have immunogenicity again, prolonged and repeated injection, yet unlikely causing allergic reaction.Transfer factor mainly is the transfer sell immunologic function, therefore, select to have the donor of selectivity immunity, effective ingredient in its leukocyte is provided, act on receptor, utilize special active immunity tissue that the usefulness of more efficiently transfer factor as the histiocyte immunity is provided.Pass through broad research in recent years, find between some different genera animal, what have also can transmit allergy, since finding that preparing transfer factor with animal can make human body sensitization, utilize the existing many successful reports of animal transfer factor treatment human diseases, as Viza with specificity cattle transfer factor treatment people herpes infection: the particularly research of specific transfer factor on anticancer, as the effective report of multiple anticancer specific transfer factor treatments such as existing anti-pulmonary carcinoma, gastric cancer.But there is no the report of relevant keratin immunity preparation specific transfer factor treatment skin peptide disease both at home and abroad.
The objective of the invention is to utilize biotechnology,,, have the specific cellular immunity of transmission effect because of selecting tissue for use through the keratin specific immune from the sheep leukocyte of immunity, extracting specific transfer factor with dialysis process.Can strengthen and adjusting body cell immunologic function by specificity, can be used for various immunologic function disorder treating for skin disease.
Advantage of the present invention;
Epiderm specificity transfer factor of the present invention, main component is multiple free amino acid, composition such as nucleotide and micromolecule polypeptide, its activity is not destroyed by trypsin, ribonucleic acid, and very little dosage just can be to receptor transfer sell immunologic function, and the persistent period can reach about 1 year, itself does not contain globulin, does not have immunogenicity again, prolonged and repeated injection, also unlikely causing allergic reaction, its immune property belongs to adoptive immunity.Clinical practice treatment psoriasis vulgaris 126 examples, 34 examples of fully recovering (26.98%), total obvious effective rate (66.7%) is obtained satisfactory effect, no toxicity.
The objective of the invention is to realize in the following manner:
Get purification specificity antigen, immune animal is got animal spleen, lymph node under the aseptic condition, and washing is rubbed, low temperature dialysis, and the membrane filtration degerming, aseptic subpackaged, can be made into the medicine of various dosage forms such as injection, oral liquid, powder.
Embodiments of the invention:
1. animal immune
1.1 select to meet " management of laboratory animal rules " goat every 20kg, immunity keratin 1mg/kg.Divide and carry out for three times.
1.2 first immunisation: the 7mg keratin antigen adds the incomplete good fortune Su Shi adjuvant of equivalent.Select multiple spot subcutaneous injections such as groin, nape, totally 8～12 points, every about 0.5ml.
1.3 immunity once more: the 7mg keratin antigen adds the same injection of the incomplete freund adjuvant of equivalent.(1 week of first immunisation back)
1.4 immunity for the third time: 6mg keratin subcutaneous injection is the same.(2 week of first immunisation back)
2. specific transfer factor preparation
2.1 get dirty, the lymph node of Lien Caprae seu ovis under the aseptic condition, wipe out peplos, fat, fibrous tissue, with rubbing 10 * 108/ml of cell behind the sterile saline cyclic washing.
2.2 be broken into homogenate from fast disperser ,-70 ℃ (to 30 ℃ of multigelations 5 times.The microscopy smudge cells reaches more than 90%, and the centrifugal precipitation of abandoning is got supernatant.
2.3 4 ℃ of normal saline dialysiss 30～40 hours, 10 * 108 cell conditioned medium liquid are to the 100ml normal saline.Bag filter requires below the molecular weight 5000D.
2.4 cured aperture 0.22 μ is filtered in filtration sterilization, adds pressure filtration in the sterilization membrane filter.
2.5 press the packing of biological product packing rules, every 2ml.
3. specific transfer factor detects, examines and determine
Carry out sterility test, pyrogen test, safety test, hypersensitive test, abnormal toxicity test, vitality test and chemical assay (PH, ultraviolet absorptivity, content of peptides, ribose content, proteins react) by biological product determination rules pertinent regulations.
Claims (2)
1. epiderm specificity transfer factor, it is characterized in that: get purification specificity antigen, immune animal is got animal spleen, lymph node under the aseptic condition, and washing is rubbed, low temperature dialysis, the membrane filtration degerming, aseptic subpackaged.
2. epiderm specificity transfer factor according to claim 1 is characterized in that: various doses the medicine that contains epiderm specificity transfer factor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011067772A CN1179727C (en) | 2001-02-28 | 2001-02-28 | Epiderm specificity transfer factor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011067772A CN1179727C (en) | 2001-02-28 | 2001-02-28 | Epiderm specificity transfer factor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1319400A true CN1319400A (en) | 2001-10-31 |
| CN1179727C CN1179727C (en) | 2004-12-15 |
Family
ID=4655750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011067772A Expired - Fee Related CN1179727C (en) | 2001-02-28 | 2001-02-28 | Epiderm specificity transfer factor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1179727C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316045A (en) * | 2013-06-26 | 2013-09-25 | 西安斯凯达生物制品有限公司 | Combined specific transfer factor for livestock and poultry and preparation method of combined specific transfer factor |
| CN104721807A (en) * | 2015-04-13 | 2015-06-24 | 刘冬明 | Oral liquid for treating psoriasis |
-
2001
- 2001-02-28 CN CNB011067772A patent/CN1179727C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316045A (en) * | 2013-06-26 | 2013-09-25 | 西安斯凯达生物制品有限公司 | Combined specific transfer factor for livestock and poultry and preparation method of combined specific transfer factor |
| CN103316045B (en) * | 2013-06-26 | 2015-08-12 | 西安斯凯达生物制品有限公司 | A kind of livestock and poultry multi-joint specific transfer factor and preparation method |
| CN104721807A (en) * | 2015-04-13 | 2015-06-24 | 刘冬明 | Oral liquid for treating psoriasis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1179727C (en) | 2004-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2156621C1 (en) | Neurotropic drug | |
| CN1057445C (en) | Method for preparing anticancer bioactive peptide preparation | |
| CN100374123C (en) | Method for extracting and purifying calf serum protein-removing extract | |
| CN102167726A (en) | Method for separating and extracting active polypeptide and immune ribonucleic acid by utilizing blood and spleen of animal | |
| CN103113462A (en) | Shark glycoprotein, and preparation method and application thereof | |
| CN1179727C (en) | Epiderm specificity transfer factor | |
| CN1121807A (en) | "Ailing" anticancer injection | |
| EP1597271A2 (en) | Peptides directed against antibodies, which cause cold-intolerance, and the use thereof | |
| CN101450967A (en) | High-purity rabies human immunoglobulin and raw material production method thereof | |
| KR101407611B1 (en) | Dioscoreae Rhizoma comprising the manufacture of a medicament for the treatment of facial nerve paralysis, and the extract beongbeop | |
| CN110664666A (en) | Multi-effect cream for promoting skin fibroblasts to secrete structural proteins | |
| CN112500477B (en) | Method for rapidly extracting human immunoglobulin from blood plasma | |
| CN105648009A (en) | Preparation method of high-Fischer-ratio oligopeptide from shark meat | |
| CN101502651A (en) | Hydrophobia, tetanus double-titer human immunoglobulin and preparation method thereof | |
| AU648800B2 (en) | Immune suppressive product | |
| CN111944043B (en) | Method for extracting IgM from plasma waste | |
| CN108165598A (en) | A kind of extracting method of pig blood antibiotic peptide | |
| RU2405560C1 (en) | Medication for brain cell protection | |
| CN111150066A (en) | Epidemic prevention immune peptide | |
| CN102603891A (en) | Method for preparing tetanus human immune globulin by double virus inactivation | |
| CN1179749C (en) | Method for preparing tumor specific transfer factors | |
| EP0308717B1 (en) | Method of treating viral encephalitis | |
| CN117126272B (en) | Antitoxin serum and preparation method thereof | |
| CN117903237A (en) | Process for preparing placenta antigen peptide complex and application thereof | |
| CN1064049C (en) | Thrombopoietin and its producing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041215 Termination date: 20200228 |